Peripheral administration of PYY 3-36 reduces caloric intake, increases postprandial insulin levels, and enhances insulin sensitivity, thermogenesis, lipolysis, and fat oxidation in both lean and obese humans as well as in nonhuman primates 36,37,38,39,40
Prep Time Dose Accuracy Sterility Stability Attach sterile needle to the pen Dial your daily dose Inject subcutaneously near the area of research interest Consistent daily timing optimizes tissue exposure Rotate injection sites to prevent local irritation Store refrigerated between uses Always use a new sterile needle for each administration
Serious side effects requiring immediate attention Pancreatitis
When GLP-1 drugs may be appropriate for lipoedema With all of the above said, there are circumstances where GLP-1 drugs may be a reasonable consideration for women with lipoedema: When prediabetes or type 2 diabetes is present and not adequately controlled through nutrition alone When chronic stress and cortisol dysregulation are significantly impairing metabolic function and the ability to lose abdominal weight, despite a well-structured nutrition protocol When these decisions are made collaboratively with a medical team that understands lipoedema and is actively monitoring muscle mass, bone health, nutritional status, and mental health In all cases, a low-inflammatory, nutritionally balanced eating approach remains essential alongside the medication: GLP-1 drugs are not a replacement for good nutrition